Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04126200 · FLOW

Participant flow

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-05-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants with Relapsed/Refractory Multiple Myeloma (RRMM) were screened to be randomized in sub-studies of this master protocol.
    id
    FG000
    title
    All Screened Participants
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        62
      type
      Screen Failed
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Completed screening but not randomized to sub study
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        271
      comment
      All participants who were screened for eligibility.
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        208
      comment
      All participants who passed screening and were randomized to sub-studies.
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        63
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 271 participants started the overall study which includes all participants who were screened for eligibility prior to enrollment. 208 participants met eligibility criteria and were randomized in the sub-studies.
recruitment Details
This master record includes data of screened participants for its sub-studies, 208887 Substudy 1 (NCT06160609), Substudy 2 (NCT07217119), Substudy 3 (NCT07084896), Substudy 4 (NCT06655818), Substudy 5 (NCT07217184), Substudy 6 (NCT07150091), Substudy 7 (NCT07150104) and only contains data collected during screening phase (Day -30 to Day 0). Results are presented separately for each sub study.
Complete source fields
groups
  1. description
    Participants with Relapsed/Refractory Multiple Myeloma (RRMM) were screened to be randomized in sub-studies of this master protocol.
    id
    FG000
    title
    All Screened Participants
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        62
      type
      Screen Failed
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Completed screening but not randomized to sub study
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        271
      comment
      All participants who were screened for eligibility.
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        208
      comment
      All participants who passed screening and were randomized to sub-studies.
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        63
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 271 participants started the overall study which includes all participants who were screened for eligibility prior to enrollment. 208 participants met eligibility criteria and were randomized in the sub-studies.
recruitment Details
This master record includes data of screened participants for its sub-studies, 208887 Substudy 1 (NCT06160609), Substudy 2 (NCT07217119), Substudy 3 (NCT07084896), Substudy 4 (NCT06655818), Substudy 5 (NCT07217184), Substudy 6 (NCT07150091), Substudy 7 (NCT07150104) and only contains data collected during screening phase (Day -30 to Day 0). Results are presented separately for each sub study.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice